Top Abstract Purchase Related
Home
>
Node
>
Subnode

Tumour necrosis factor inhibitors--what we need to know

Hasan, U.

New Zealand Medical Journal 119(1246): U2336

2006

ISSN/ISBN: 1175-8716
PMID: 17151710
Document Number: 603589
Biologics have revolutionised the treatment of various autoimmune diseases. Earlier in 2006, New Zealand's Pharmaceutical Management Agency (PHARMAC) approved adalimumab (anti-tumour necrosis factor [TNF] agent) for treatment of severe, unresponsive rheumatoid arthritis in adult patients. Etanercept has been available for chronic juvenile arthritis in selected, younger patients in New Zealand. This review article describes some of the common adverse events related to anti-TNF inhibitors and the importance of establishing guidelines for surveillance in the New Zealand health system.

Document emailed within 1 workday
Secure & encrypted payments

Sundrarjun, T.; Komindr, S.; Archararit, N.; Dahlan, W.; Puchaiwatananon, O.; Angthararak, S.; Udomsuppayakul, U.; Chuncharunee, S. 2004: Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis Journal of International Medical Research 32(5): 443-454
De Filippis, L.; Caliri, A.; Anghelone, S.; Scibilia, G.; Lo Gullo, R.; Bagnato, G. 2006: Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis Panminerva Medica 48(2): 129-135
Suffys, P.; Beyaert, R.; Van Roy, F.; Fiers, W. 1987: Reduced tumour necrosis factor-induced cytotoxicity by inhibitors of the arachidonic acid metabolism Biochemical and Biophysical Research Communications 149(2): 735-743
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103
Omair, M.A.; Phumethum, V.; Johnson, S.R. 2012: Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis Clinical and Experimental Rheumatology 30(2 Suppl 71: S55-S59
Browne, W.L.; Wilson, W.R.; Baguley, B.C.; Ching, L.M. 1998: Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid Anticancer Research 18(6a): 4409-4413
Kavanaugh, A.; Marzo-Ortega, H.; Vender, R.; Wei, C-Chung.; Birt, J.; Adams, D.H.; Benichou, O.; Lin, C-Yen.; Nash, P. 2019: Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks Clinical and Experimental Rheumatology 37(4): 566-574
Green, L.J..; Yamauchi, P.S..; Kircik, L.H.. 2019: Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients with Psoriasis Journal of Drugs in Dermatology: Jdd 18(8): 776-788
McLaughlin, P.J.; Aikawa, A.A.; Davies, H.M.; Bakran, A.; Sells, R.A.; Johnson, P.M. 1991: Tumour necrosis factor in renal transplantation Transplantation Proceedings 23(1 Part 2): 1289-1290
Campbell, D.A.; Li Kam Wa, E.; Britton, J.; Holgate, S.T.; Markham, A.F.; Morrison, J.F. 1996: Polymorphism at the tumour necrosis factor locus and asthma Monographs in Allergy 33: 125-137
Jayasinghe, K.S.; Ariaratnam, A. 1994: Tumour necrosis factor (TNF) in Russell's viper envenomation Ceylon Medical Journal 39(2): 112-113
Cohen, J.; Exley, A.R. 1993: Treatment of septic shock with antibodies to tumour necrosis factor Schweizerische Medizinische Wochenschrift 123(11): 492-496
Jackson, G.D.; Dai, Y.; Fung, C.; Hansen, P.G. 1995: Tumour necrosis factor alpha--a constitutive protein of bile Advances in Experimental Medicine and Biology 371b: 1083-1086
O'Reilly, D.A.; Dunlop, S.; Sargen, K.; Demaine, A.; Wilkinson, S.; Kingsnorth, A.N. 2006: Tumour necrosis factor microsatellite haplotypes are associated with chronic pancreatitis Jop: Journal of the Pancreas 7(1): 14-26
Fukui, T.; Yamagishi, J.; Furutani, Y.; Notake, M.; Yamayoshi, M.; Nomura, H.; Yamada, M.; Nakamura, S. 1985: Efficient production of a human tumour necrosis factor in Escherichia coli Nucleic Acids Symposium Series 1985(16): 273-276
Ip, K.; Hartley, L.; Solanki, K.; White, D. 2015: Retention on anti-tumour necrosis factor therapy: the Waikato experience New Zealand Medical Journal 128(1415): 34-40
An, H-Jin.; Seo, M-Jun.; Choi, I-Young.; Park, R-Kil.; Jeong, S.; Lee, J-Young.; Kim, H-Min.; Um, J-Young.; Hong, S-Heon. 2008: Induction of nitric oxide & tumour necrosis factor-alpha by Psoralea corylifolia Indian Journal of Medical Research 128(6): 752-758
Pennica, D.; Nedwin, G.E.; Hayflick, J.S.; Seeburg, P.H.; Derynck, R.; Palladino, M.A.; Kohr, W.J.; Aggarwal, B.B.; Goeddel, D.V. 1984: Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin Nature 312(5996): 724-729
Naylor, M.S.; Malik, S.T.; Stamp, G.W.; Jobling, T.; Balkwill, F.R. 1990: In situ detection of tumour necrosis factor in human ovarian cancer specimens European Journal of Cancer 26(10): 1027-1030
Yoshida, A.; Kohchi, C.; Inagawa, H.; Nishizawa, T.; Hori, H.; Soma, G.-I. 2006: A soluble 17 kDa tumour necrosis factor (TNF) mutein, TNF-SAM2, with membrane-bound TNF-like biological characteristics Anticancer Research 26(6a): 4003-4007